STAREE Trial Results | Statin Efficacy in Older Adults

Clinical Findings on Statin Therapy in Older Adults

Researchers presenting at the ESC Congress 2026 revealed new data on the use of atorvastatin among healthy, community-dwelling adults aged 70 and older. The study, titled STAREE, enrolled nearly 5,000 participants who had no prior history of cardiovascular disease, dementia, or diabetes. Half of the participants received a daily 40 mg dose of atorvastatin, while the other half received a placebo. Roughly 52% of the group consisted of women.

Over the course of approximately six years, those in the atorvastatin group experienced a 30% relative reduction in major cardiovascular events. These events included nonfatal myocardial infarction, stroke, death from cardiovascular causes, or coronary revascularization. While this primary outcome showed statistical significance, the clinical picture remains mixed. The researchers noted that 297 individuals in the active treatment group hit the primary endpoint, compared with 412 participants in the control group.

Impact on Disability-Free Survival

Despite the reduction in heart-related incidents, the trial failed to demonstrate an improvement in disability-free survival for participants. The data indicates that deaths from any cause, physical disability, and dementia occurred at similar rates in both the treatment and placebo cohorts. Specifically, 637 participants in the atorvastatin group reached these non-cardiovascular endpoints, against 676 participants in the placebo group.

Serious adverse events emerged at a rate of 2.7% across both groups. However, the researchers observed a higher frequency of musculoskeletal, hepatobiliary, and diabetes-related adverse events among those taking the medication. These side effects highlight a trade-off for older patients who may be managing multiple health conditions simultaneously. The study findings were simultaneously published in the New England Journal of Medicine to provide immediate access for clinicians.

Future Clinical Implications

Lead investigator Sophia Zoungas of Monash University emphasized the importance of these results for a global population that continues to age. She noted that managing the risk of stroke and heart attack remains a primary concern for older adults and their families. While statins provide an effective mechanism for lowering specific cardiovascular risks, this study shows they do not act as a panacea for extending overall disability-free longevity.

Statins have long served as a standard tool in preventative cardiology for younger populations. This trial now adds a specific layer of evidence for practitioners making decisions for patients over 70. Clinicians must now balance the lower incidence of nonfatal cardiovascular events against the documented increase in specific side effects. The medical community expects updated guidelines to reflect these findings, potentially shifting how practitioners approach cholesterol management in the elderly.

As the medical field continues to interpret these results, the focus shifts to how doctors should weigh the absolute benefit of avoiding a heart attack against the potential impact on quality of life for the oldest segment of society. Future longitudinal studies will likely monitor these patients to see if long-term outcomes differ as the cohort ages further. For now, the takeaway for the cardiology community involves a more nuanced approach to prescribing statins for primary prevention in healthy older populations.